VEA
NRIX icon

Virtus ETF Advisers’s Nurix Therapeutics NRIX Stock Holding History

Virtus ETF Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,458
Closed -$65.1K – 660
2024
Q4 		$65.1K Sell
3,458
-2,054
-37% -$47.1K 0.03% 420
2024
Q3 		$124K Buy
5,512
+101
+2% +$2.29K 0.06% 348
2024
Q2 		$113K Sell
5,411
-4,282
-44% -$66.7K 0.06% 329
2024
Q1 		$142K Sell
9,693
-663
-6% -$7.13K 0.08% 335
2023
Q4 		$107K Buy
10,356
+1,345
+15% +$9.22K 0.07% 334
2023
Q3 		$70.8K Sell
9,011
-901
-9% -$8.23K 0.04% 383
2023
Q2 		$99K Buy
9,912
+1,731
+21% +$17.7K 0.06% 386
2023
Q1 		$72.6K Sell
8,181
-3,151
-28% -$32.8K 0.04% 399
2022
Q4 		$124K Buy
11,332
+519
+5% +$6.26K 0.07% 409
2022
Q3 		$141K Buy
10,813
+78
+0.7% +$1.24K 0.06% 363
2022
Q2 		$136K Buy
10,735
+5,059
+89% +$57.3K 0.05% 336
2022
Q1 		$80K Sell
5,676
-334
-6% -$5.93K 0.04% 337
2021
Q4 		$174K Sell
6,010
-1,183
-16% -$35.9K 0.07% 266
2021
Q3 		$216K Sell
7,193
-377
-5% -$11.6K 0.1% 249
2021
Q2 		$201K Buy
+7,570
New +$222K 0.08% 342

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's NRIX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 3,458 shares — an estimated $65.1K sold.

Virtus ETF Advisers first reported a position in NRIX in Q2 2021 and held it in 15 quarters. The position peaked at $216K in Q3 2021. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,458 Nurix Therapeutics shares in Q1 2025, an estimated $65.1K.
  • Virtus ETF Advisers first reported a position in Nurix Therapeutics in Q2 2021 and held it in 15 quarters.
  • Virtus ETF Advisers's Nurix Therapeutics position peaked at $216K in Q3 2021.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.